Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: GlobeNewswire
Detailed Characterization of Unique DolaLock Technology Enhancements to Drug Efficacy and Tolerability XMT-1522 Demonstrates Synergy in Combination with a Checkpoint Inhibitor CAMBRIDGE, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other proprietary platforms, today announced new data on Mersana’s lead ADC platform, Dolaflexin, and on the HER2 targeted ADC XMT-1522, presented as part of the 2018 American Association for Cancer Research (AACR) Annual Meeting being held April 14-18 in Chicago, IL. “The data presented in these posters demonstrate the benefits of our differentiated approach to ADCs,” said Timothy B. Lowinger, Chief Scientific Officer, Mersana Therapeutics. “The DolaLock controlled bystander effect represents a unique approach to enhance both efficacy and tolerability. In addit
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. They now have a $5.00 price target on the stock.MarketBeat
- AVLX, SGH and ETNB are among pre market losers [Seeking Alpha]Seeking Alpha
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.MarketBeat
- Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
MRSN
Earnings
- 2/28/24 - Beat
MRSN
Sec Filings
- 4/3/24 - Form 4
- 2/28/24 - Form 8-K
- 2/28/24 - Form 424B5
- MRSN's page on the SEC website